Schorer M, Rakebrandt N, Lambert K, Hunziker A, Pallmer K, Oxenius A, et al. TIGIT limits immune pathology during viral infections. Nat Commun. 2020;11:1288 pubmed publisher

Dixon K, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. J Immunol. 2018;200:3000-3007 pubmed publisher

Trsan T, Vuković K, Filipović P, Brizić A, Lemmermann N, Schober K, et al. Cytomegalovirus vector expressing RAE-1? induces enhanced anti-tumor capacity of murine CD8+ T cells. Eur J Immunol. 2017;47:1354-1367 pubmed publisher

Kourepini E, Paschalidis N, Simoes D, Aggelakopoulou M, Grogan J, Panoutsakopoulou V. TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease. J Immunol. 2016;196:3570-80 pubmed publisher

Burton B, Britton G, Fang H, Verhagen J, Smithers B, Sabatos Peyton C, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5:4741 pubmed publisher

Chan C, Martinet L, Gilfillan S, Souza Fonseca Guimaraes F, Chow M, Town L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:431-8 pubmed publisher

Foks A, Ran I, Frodermann V, Bot I, Van Santbrink P, Kuiper J, et al. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. PLoS ONE. 2013;8:e83134 pubmed publisher

Joller N, Hafler J, Brynedal B, Kassam N, Spoerl S, Levin S, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338-42 pubmed publisher